Molecular biological characterization of phosphodiesterase 3A from human corpus cavernosum

被引:9
作者
Küthe, A
Eckel, H
Stief, CG
Uckert, S
Forssmann, WG
Jonas, U
Mägert, HJ
机构
[1] Hannover Med Sch, Dept Urol, D-30625 Hannover, Germany
[2] Lower Saxony Inst Peptide Res, D-30625 Hannover, Germany
关键词
corpus cavernosum penis; erectile dysfunction; phosphodiesterase; PDE;
D O I
10.1016/S0009-2797(99)00074-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The hydrolysis of the second messenger cyclic AMP (cAMP) by phosphodiesterase 3 (PDE3) is known to play an important regulatory role in the context of relaxation of cavernous smooth muscle of the penis. Thus, we investigated the PDE3A isoform from penile cavernous tissues of male patients with and without symptoms of erectile dysfunction at the molecular biological level. As revealed by reverse transcriptase polymerase chain reaction, of all tissues of the urogenital tract analyzed the expression of the PDE3A gene was highest in the corpus cavernosum However, significant differences in the levels of gene expression were not found between the two subgroups of patients. Also, the determined nucleotide sequences of the cloned penile PDE3A cDNAs of all patients were absolutely identical. Surprisingly, some deviations could be detected in the cDNA sequences of PDE3A from human myocard and platelets. The data obtained indicate that neither the expression levels nor the sequence deviations of PDE3A are the main reasons for erectile dysfunction in men. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:593 / 598
页数:6
相关论文
共 18 条
[1]   PRIMARY SEQUENCE OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES AND THE DESIGN OF SELECTIVE INHIBITORS [J].
BEAVO, JA ;
REIFSNYDER, DH .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (04) :150-155
[2]  
BENTLEY J K, 1992, Current Opinion in Cell Biology, V4, P233
[3]  
Boolell M, 1996, Int J Impot Res, V8, P47
[4]   9-benzyladenines: Potent and selective cAMP phosphodiesterase inhibitors [J].
Bourguignon, JJ ;
Desaubry, L ;
Raboisson, P ;
Wermuth, CG ;
Lugnier, C .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (12) :1768-1770
[5]  
Burns F, 1996, Adv Pharmacol, V36, P29, DOI 10.1016/S1054-3589(08)60575-X
[6]   Human platelet cGI-PDE: Expression in yeast and localization of the catalytic domain by deletion mutagenesis [J].
Cheung, PP ;
Xu, H ;
McLaughlin, MM ;
Ghazaleh, FA ;
Livi, GP ;
Colman, RW .
BLOOD, 1996, 88 (04) :1321-1329
[7]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[8]  
HALL IP, 1993, BRIT J CLIN PHARMACO, V35, P1
[9]   TYPE-III CGMP-INHIBITED CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES (PDE-3 GENE FAMILY) [J].
MANGANIELLO, VC ;
TAIRA, M ;
DEGERMAN, E ;
BELFRAGE, P .
CELLULAR SIGNALLING, 1995, 7 (05) :445-455
[10]   MOLECULAR-CLONING AND EXPRESSION OF HUMAN MYOCARDIAL CGMP-INHIBITED CAMP PHOSPHODIESTERASE [J].
MEACCI, E ;
TAIRA, M ;
MOOS, M ;
SMITH, CJ ;
MOVSESIAN, MA ;
DEGERMAN, E ;
BELFRAGE, P ;
MANGANIELLO, V .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (09) :3721-3725